NEPHSTROM for Diabetic Kidney Disease

Diabetic Kidney Disease Clinical Trial

— NEPHSTROM  

Official title:

Novel Stromal Cell Therapy for Diabetic Kidney Disease (NEPHSTROM Study)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02585622
• Other study ID #: NEPHSTROM
• Secondary ID: 2016-000661-23
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: December 11, 2017
• Est. completion date: March 2024

Study information

• Verified date: December 2023
• Source: Mario Negri Institute for Pharmacological Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will investigate, primarily, the safety, feasibility and tolerability and, secondarily, the preliminary efficacy of an allogeneic bone marrow-derived Mesenchymal Stromal Cell (MSC) therapy (ORBCEL-M) in study subjects with type 2 diabetes (T2D) and progressive diabetic kidney disease (DKD).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 48
• Est. completion date: March 2024
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 85 Years

Eligibility

Inclusion Criteria:

• Male and female = 40 years and <85 years old. ;

• T2D for 3 or more years under a clinician with mandated responsibility for management of the patients to national guidelines;

• Urinary albumin excretion (UAE) = 60 µg/min (in a 24 hour urine collection) and urine albumin-to-creatinine ratio (UACR) = 88 mg/g (= 10 mg/mmol) (in a spot morning urine collection);

• Estimated GFR (eGFR) 30-50 ml/min/1.73 m^2 by the CKD-EPI equation on 2 or more consecutive measurements at least 30 days apart within the past 6 months;

• A documented decline of eGFR of = -10ml/min/1.73 m^2 over the past 3 years or documented rate of eGFR decline of = -5 ml/min/1.73 m^2 year based on 3 or more consecutive readings at least 90 days apart in the past 18 months;

• Lack of suspicion of renal diagnosis other than DKD;

• Willing and able to provide written informed consent.

Exclusion Criteria:

1. Current resting systolic BP = 150 mmHg and current resting diastolic BP = 90 mmHg in a clinical setting, despite treatment with 3 hypertensive agents of different classes (including one diuretic), measured in a quiet environment with morning medications already taken;

2. Initiation of a new anti-hypertensive agent within the past 6 months

3. Increase the dose of an anti-hypertensive agent by = 100% of the previous dose within the past 3 months

Exclusion criteria related to glycaemic control:

4. Current HbA1c > 75 mmol/mol (> 9%)

5. Initiation of a new hypoglycaemic agent within the past 6 months

6. Increase the dose of a hypoglycaemic agent by = 100% of the previous dose within the past 3 months

Exclusion criteria related to dyslipidaemia:

7. Current fasting total cholesterol > 7 mmol/l

8. Current fasting total triglycerides > 3.5 mmol/l

9. Initiation of a new lipid lowering agent within the past 6 months

Other exclusion criteria:

10. Chronic lung or liver disease;

11. Cardiovascular events (myocardial infarction, stroke or acute limb ischemia) within 6 months prior to enrolment;

12. Current or history within 6 months prior to enrolment of NYHA class III or IV heart failure;

13. Other concomitant disease or conditions in the opinion of the investigator that are likely to pose risk to the patient and that would render the patient unsuitable for participation or that could impair patient safety or ability to participate in the study, such as active malignancy;

14. Irreversible disease or condition for which 6-month mortality is estimated to be greater than 50%;

15. Positive screening test for clinically significant anti-HLA antibodies. An initial antibody screening with Luminex® multi-antigen beads to detect class I and class II MHC antibodies followed by a Luminex single antigen bead assay to determine the specificity of any antibody detected. Potential study subjects with positive screening for any clinically significant anti-HLA antibody will be excluded and will not be eligible to participate in the NEPHSTROM clinical study (MFI>1500);

16. History or presence of any medical condition or disease which, in the opinion of the Investigator may place the participant at unacceptable risk for study participation;

17. Childbearing potential without use of effective acceptable methods of contraception. Women of childbearing potential can only be included in the study if a pregnancy test is negative at the screening visit (V1) and at baseline visit (V2) if they agree to use adequate contraception. Adequate contraception is defined as any combination of at least two effective methods of birth control, of which at least one is a physical barrier (e.g. condoms with hormonal contraception or implants or combined oral contraceptives, certain intrauterine devices). Women are considered post-menopausal and not of child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate) or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL or have had surgical treatment such as bilateral tubal ligation, bilateral oophorectomy, or hysterectomy.

18. Pregnancy or lactating;

19. Participation in other investigational medicinal product (IMP) trials within 30 days before the inclusion or concurrent to this study (18 month follow-up);

20. Inability to understand the potential risks and benefits of the study;

21. Legal incapacity.

Related Conditions & MeSH terms

• Diabetic Kidney Disease
• Diabetic Nephropathies
• Kidney Diseases

Intervention

Biological:
• Mesenchymal Stromal Cells
Cells will be administered intravenously at 3 different doses (80, 160, or 240 x 10^6, fixed dose) over 10-20 minutes. Volume total of fluid infused: 40 ml

Other:
• Placebo
Volume total of fluid infused: 40 ml

Locations

Country	Name	City	State
Ireland	National University of ireland - Galway University Hospital -Regenerative Medicine Institute	Galway
Italy	ASST - Papa Giovanni XXIII - U.O. Nefrologia e Dialisi/ Mario Negri Institute for Pharmacological Research - Clinical Research Center for Rare Diseases Aldo e Cele Daccò	Bergamo	BG
United Kingdom	Belfast Health and Social Care Trust - Belfast City Hospital	Belfast
United Kingdom	University Hospital Birmingham NHS Foundation Trust - Queen Elizabeth Medical Centre	Birmingham

Sponsors (8)

Lead Sponsor	Collaborator
Mario Negri Institute for Pharmacological Research	ASST Papa Giovanni XXIII, Bergamo, Italy, Belfast Health and Social Care Trust, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri - Bergamo, Italy, Leiden University Medical Center, National University of Ireland, Galway, Ireland, NHS Blood and Transplant, University Hospital Birmingham, NHS Foundation Trust, Hospital, Birmingham, UK

Countries where clinical trial is conducted

Ireland,  Italy,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number and severity of all pre-specified infusion-associated events and the overall number and frequency of adverse events.	At each visit overall clinical condition of the patient will be evaluated and any adverse event wil be recorded.	Changes from baseline to study completion, up to 18 months after cell or placebo infusion.
Secondary	Glomerular filtration rate (GFR)	GFR will be measured by plasma clearance of unlabelled exogenous marker Iohexol and estimated by CKD-EPI and MDRD equations.	Changes from baseline up to 18 months after cell or placebo infusion.
Secondary	Urinary Albumin/Creatinine Ratio (ACR)	ACR will be measured on spot morning urine samples.	Changes from baseline at 6 months and then every six months to study completion,up to 18 months after cell or placebo infusion.
Secondary	Urinary albumin excretion (UAE).	UAE will be measured on 24h urine samples using standardized methods.	Changes from baseline at 6 months and then every six months to study completion,up to 18 months after cell or placebo infusion.
Secondary	Fasting blood glucose (target <126mg/dL)		Proportion of study participants within target range (<126mg/dL) at baseline and at each time point (day 1, day 7, month 1,3,6,12,18 after cell or placebo infusion).
Secondary	HbA1c (target <75mmol/mol or <9%)		Proportion of study participants within target range (<75mmol/mol or <9%) at baseline and at each time point (day 1, day 7, month 1,3,6,12,18 after cell or placebo infusion).
Secondary	Total cholesterol (target <200 mg/dl)		Proportion of study participants within target range (<200 mg/dl) at baseline and at each time point (day 1, day 7, month 1,3,6,12,18 after cell or placebo infusion).
Secondary	LDL cholesterol (target <100 mg/dl)		Proportion of study participants within target range (<100 mg/dl) at baseline and at each time point (day 1, day 7, month 1,3,6,12,18 after cell or placebo infusion).
Secondary	Triglycerides (target <170 mg/dl)		Proportion of study participants within target range (<170 mg/dl) at baseline and at each time point (day 1, day 7, month 1,3,6,12,18 after cell or placebo infusion).
Secondary	Arterial blood pressure (the target value <130/80 mmHg)		Proportion of study participants within target range (<130/80 mmHg)at baseline and at each time point (day 1, day 7, month 1,3,6,12,18 after cell or placebo infusion).
Secondary	Quality of life	Quality of life will be evaluated by the administration of SF36 questionnaire.	Changes from baseline to 1,3,6,12 and 18 months after cell or placebo infusion.
Secondary	Quality of life	Quality of life will be evaluated by the administration of EQ-5D-5L questionnaire.	Changes from baseline to 1,3,6,12 and 18 months after cell or placebo infusion.
Secondary	Anti-HLA antibody development		Changes from baseline to 3,12 and 18 months after cell or placebo infusion.
Secondary	Inflammation and fibrosis related soluble mediators	Blood and urine bio-chip-based multiplex assay	Changes from baseline to 7 days, 1,6,12 and 18 months after cell or placebo infusion.
Secondary	Serum/plasma concentrations (pg/ml) of biomarkers of inflammation.	Biomarkers will include sTNFR1, sTNFR2, Il-6,TNF-alfa, IL-1beta, MCP-1 (CCL2), IL-8, FGF21.	Changes from baseline to 7 days, 1,6,12 and 18 months after cell or placebo infusion.
Secondary	Serum/plasma concentrations (ng/ml) of biomarkers of CKD progression.	Biomarkers will include Cystatin C, NGAL, Adiponectin, Leptin.	Changes from baseline to 7 days, 1,6,12 and 18 months after cell or placebo infusion.
Secondary	Urine concentrations (pg/ml adjusted to urine creatinine concentration) of biomarkers of inflammation.	Biomarkers will include sTNFR1, sTNFR2, Il-6,TNF-alfa, IL-1beta, MCP-1 (CCL2), IL-8.	Changes from baseline to 7 days, 1,6,12 and 18 months after cell or placebo infusion.
Secondary	Proportion/total number of circulating T cells, B cells, NK cells, monocytes, dendritic cells		Changes from baseline to 7 days, 1,6,12 and 18 months after cell or placebo infusion.
Secondary	Cost-effectiveness of cell therapy	Cost-effectiveness of cell therapy will be evaluated by providing the patients with a healthcare resource diary.	Changes from baseline to 1,3,6,12 and 18 months after cell or placebo infusion.